See more : Western Magnesium Corporation (WMG.V) Income Statement Analysis – Financial Results
Complete financial analysis of Evolent Health, Inc. (EVH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evolent Health, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Giant Biogene Holding Co., Ltd. (2367.HK) Income Statement Analysis – Financial Results
- 3P Learning Limited (3PL.AX) Income Statement Analysis – Financial Results
- HUTCHMED (China) Limited (HCM) Income Statement Analysis – Financial Results
- Zuari Industries Limited (ZUARIGLOB.NS) Income Statement Analysis – Financial Results
- Isramco Negev 2 Limited Partnership (ISRA.TA) Income Statement Analysis – Financial Results
Evolent Health, Inc. (EVH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.evolenthealth.com
About Evolent Health, Inc.
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.96B | 1.35B | 907.96M | 1.02B | 846.38M | 627.06M | 434.95M | 254.19M | 96.88M | 0.00 | 25.67M | 8.35M |
| Cost of Revenue | 1.50B | 1.04B | 657.55M | 701.37M | 513.06M | 327.83M | 269.35M | 155.18M | 57.40M | 0.00 | 30.02M | 11.27M |
| Gross Profit | 460.47M | 316.58M | 250.41M | 321.06M | 333.32M | 299.24M | 165.60M | 99.01M | 39.48M | 0.00 | -4.35M | -2.93M |
| Gross Profit Ratio | 23.45% | 23.42% | 27.58% | 31.40% | 39.38% | 47.72% | 38.07% | 38.95% | 40.75% | 0.00% | -16.93% | -35.08% |
| Research & Development | 0.00 | 27.00M | 15.50M | 15.10M | 19.80M | 18.20M | 17.20M | 11.10M | 5.80M | 0.00 | 2.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 358.11M | 269.27M | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 15.98M |
| Other Expenses | 173.57M | 67.20M | 60.04M | 61.48M | 60.91M | 109.00K | 171.00K | 4.00K | 7.17M | -25.25M | 1.00K | 0.00 |
| Operating Expenses | 531.68M | 336.46M | 279.54M | 372.03M | 453.73M | 350.82M | 238.04M | 177.92M | 82.45M | -25.25M | 16.81M | 16.69M |
| Cost & Expenses | 2.04B | 1.37B | 937.09M | 1.07B | 966.79M | 678.65M | 507.39M | 333.09M | 139.85M | -25.25M | 46.83M | 27.96M |
| Interest Income | 5.26M | 1.37M | 407.00K | 3.16M | 3.99M | 3.44M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 | 18.00K |
| Interest Expense | 54.21M | 15.57M | 25.43M | 28.34M | 14.53M | 5.48M | 3.64M | 723.00K | 293.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.42M | 90.25M | 60.04M | 60.84M | 66.64M | 44.52M | 32.37M | 17.22M | 7.17M | 0.00 | 1.21M | 114.00K |
| EBITDA | -24.79M | 43.75M | 55.66M | -241.38M | -245.95M | -4.15M | -40.40M | -220.31M | -31.51M | -25.25M | -20.35M | -19.51M |
| EBITDA Ratio | -1.26% | 0.54% | 9.94% | 2.31% | -7.73% | -1.32% | -9.20% | 38.10% | -464.44% | 0.00% | -257.85% | -233.70% |
| Operating Income | -71.21M | -59.84M | 30.25M | -37.88M | -120.41M | -47.48M | -72.84M | -237.42M | -42.97M | -25.25M | -21.16M | -19.62M |
| Operating Income Ratio | -3.63% | -4.43% | 3.33% | -3.71% | -14.23% | -7.57% | -16.75% | -93.40% | -44.36% | 0.00% | -82.41% | -235.07% |
| Total Other Income/Expenses | -131.19M | -65.72M | 12.61M | -67.69M | -18.23M | -6.67M | -3.56M | -114.00K | 386.26M | -25.25M | 41.19M | 19.00K |
| Income Before Tax | -202.41M | -62.08M | -29.80M | -337.80M | -327.12M | -54.15M | -76.40M | -237.53M | 343.29M | -25.25M | 20.03M | -19.60M |
| Income Before Tax Ratio | -10.31% | -4.59% | -3.28% | -33.04% | -38.65% | -8.64% | -17.57% | -93.45% | 354.35% | 0.00% | 78.03% | -234.84% |
| Income Tax Expense | -89.37M | -43.38M | 483.00K | -3.55M | -21.54M | 40.00K | -6.64M | -10.76M | 23.48M | 0.00 | 8.00K | 337.00K |
| Net Income | -113.04M | -18.70M | -30.28M | -334.25M | -305.58M | -52.66M | -60.67M | -159.74M | 332.49M | -25.25M | 20.02M | -19.26M |
| Net Income Ratio | -5.76% | -1.38% | -3.34% | -32.69% | -36.10% | -8.40% | -13.95% | -62.84% | 343.21% | 0.00% | 78.00% | -230.81% |
| EPS | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 13.14 | -0.66 | 0.06 | -1.13K |
| EPS Diluted | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 6.93 | -0.66 | 0.06 | -1.13K |
| Weighted Avg Shares Out | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.00M | 25.13M | 38.23M | 38.23M | 17.00K |
| Weighted Avg Shares Out (Dil) | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.03M | 46.14M | 38.23M | 38.23M | 17.00K |
Evolent Health to Participate in Upcoming Conferences
Evolent Health, Inc. (EVH) Q4 2022 Earnings Call Transcript
Evolent Health (EVH) Surpasses Q4 Earnings and Revenue Estimates
Evolent Health Announces Fourth Quarter and Full Year 2022 Results
Evolent Health: Strengthening Fundamentals, Investing At High Rates Of Return
SignalFire Announces $900M+ in Funding and Launch of Executive-in-Residence Program
Evolent Health, Inc. to Release Fourth Quarter Financial Results and Host Conference Call on Wednesday, February 22, 2023
Evolent Health to Participate in Upcoming Conferences
Evolent Health: A Bit Complex, But Interesting
Centene agrees to sell benefit-management unit to Evolent Health for $750 million
Source: https://incomestatements.info
Category: Stock Reports